A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.
Advanced Malignant Solid Tumor
DRUG: 9MW3811 Injection
Incidence of adverse events (AEs) as assessed by CTCAE v5.0, An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment., up to 24 weeks|Incidence of dose-limiting toxicity (DLT) as assessed by CTCAE v5.0, A DLT is defined as any of the adverse drug reactions listed in the protocol that will be assessed during Cycle 1, Cycle 1 Day 1 to Cycle 1 Day 21
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators, To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Disease Control Rate (DCR), According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators, To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Duration of Response (DoR), According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators, To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Progression Free Survival (PFS), According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators, To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Maximum Plasma Concentration (Cmax), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Time to reach Cmax (Tmax), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Terminal elimination half-life (t1/2), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|AUC from time 0 extrapolated to infinity (AUC0-inf), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Terminal elimination rate constant (Î»z), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Apparent clearance (CL), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Volume of distribution (Vz), To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors., up to 24 weeks|Incidence of antidrug antibodies (ADA) at specified timepoints relative to baseline, To determine the immunogenicity of 9MW3811., up to 24 weeks
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.